

In the Claims

Please amend the claims as follows:

1. (CURRENTLY AMENDED) An isolated ~~mammalian~~ nucleic acid molecule selected from the group consisting of:

(a) nucleic ~~Nucleic~~ acid molecules encoding T128 polypeptide (SEQ ID NO: 1) ~~as shown in Figure 1~~, a polypeptide at least 80% identical to SEQ ID NO: 1 T128, or a fragment thereof, which is capable of cross-reacting with sera from patients with prostate ~~cancer~~ cancer;

(b) nucleic ~~Nucleic~~ acid molecules comprising the nucleotide sequence ~~depicted between nucleic acid residues 642 and 1688 of SEQ ID NO: 2; the sequence shown in Figure 2.~~

(c) nucleic ~~Nucleic~~ acid molecules, the complementary strand of which specifically hybridises to a nucleic acid molecule in (a) or ~~(b)~~ (b); and

(d) nucleic ~~Nucleic~~ acid molecules the sequence of which differs from the sequence of the nucleic acid molecule ~~of (C) in (a), (b), or (c)~~ due to the degeneracy of the genetic code.

2. (CURRENTLY AMENDED) An isolated nucleic acid molecule according to ~~claim 2~~ claim 1, encoding the polypeptide sequence ~~shown in Figure 1 of SEQ ID NO: 1.~~

3. (CURRENTLY AMENDED) An isolated nucleic acid molecule which is at least 80% homologous to ~~a the nucleic acid sequence molecule according to as defined in claim 1 or claim 2~~ and which encodes a polypeptide which is expressed in higher concentrations in cancerous tissue compared to that tissue when in a normal state.

~~14. 4.~~ (CURRENTLY AMENDED) An isolated nucleic acid molecule comprising at least 15 nucleic acids capable of specifically hybridising to a sequence within a nucleic acid molecule according to claim 1 ~~any preceding claim.~~

5. (CURRENTLY AMENDED) A vector comprising a nucleic acid molecule according to claim 1 ~~any preceding claim.~~

6. (CURRENTLY AMENDED) A host cell comprising a vector according to claim 5.

7. (CURRENTLY AMENDED) An isolated protein comprising an amino acid sequence encoded by a nucleic acid molecule according to claim 1 ~~any preceding claim~~.

8. (CURRENTLY AMENDED) An isolated protein according to claim 7 which comprises the amino acid sequence of SEQ ID NO: 1 ~~shown in Figure 1~~.

9. (CURRENTLY AMENDED) A fragment or derivative of a ~~polypeptide~~ the protein according to claim 7 ~~or claim 8~~.

10. (CURRENTLY AMENDED) A monoclonal antibody capable of specifically binding to ~~a~~ the protein of claim 7, polypeptide, or a fragment or derivative thereof ~~according to any one of claims 7 to 9~~.

11. to 12. (CANCELED)

~~11. (ORIGINAL) The use of an isolated nucleic acid molecule comprising a sequence according to any one of claims 1 to 4 to detect or monitor cancer.~~

~~12. (ORIGINAL) The use of a nucleic acid probe which is capable of specifically hybridising an isolated nucleic acid molecule according to any of claims 1 to 4.~~

13. (CURRENTLY AMENDED) A method of detecting or monitoring cancer in a patient comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising ~~a sequence~~ the nucleic acid molecule according to ~~claims 1 to 4~~ claim 1 in a sample from ~~a~~ the patient.

14. (CURRENTLY AMENDED) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 ~~use of a nucleic acid molecule or probe according to claim 11 or claim 12~~ in combination with a reverse transcription polymerase chain reaction (RT-PCR).

15. (CURRENTLY AMENDED) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a polypeptide the protein according to claim 7 ~~any of claims 7 to 9~~.

16. (CURRENTLY AMENDED) A The method according to claim 15 wherein the detecting or monitoring step includes a monoclonal ~~comprising the use of an antibody selective for and capable of a protein or peptide as defined in any of claims 7 to 9 to detecting the protein or peptide.~~

17. (CURRENTLY AMENDED) A ~~The~~ method according to claim 16 wherein the detecting or monitoring step includes an Enzyme-Linked ImmunoSorbant Assay comprising the use of an ~~Enzyme-linked ImmunoSorbant Assay (ELISA)~~.

18. (CURRENTLY AMENDED) ~~Use or~~ The method according to claim 13 any one of claims 11 to 17, wherein the cancer is a gastro-intestinal cancer, kidney cancer or a prostate cancer.

19. (CURRENTLY AMENDED) A kit comprising the nucleic acid molecule as defined in claim 1 for use with a method of detecting or monitoring cancer ~~according to any one of claims 13 to 18 comprising a nucleic acid, protein or peptide, or an antibody as defined in any one of claims 1 to 4 or 8 to 10.~~

20. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a nucleic acid molecule comprising a the nucleic acid sequence molecule according to claim 1 ~~any of claims 1 to 4 or~~ a pharmaceutically effective fragment thereof.

21. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a nucleic acid molecule hybridisable under high stringency conditions to a nucleic acid molecule comprising a the nucleic acid sequence molecule according to claim 1 ~~any of claims 1 to 4 or~~ a pharmaceutically effective fragment thereof.

22. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a ~~polypeptide the protein~~ according to claim 7 ~~as defined in any of claims 7 to 9 or~~ a pharmaceutically effective fragment thereof.

23. (CURRENTLY AMENDED) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of ~~an~~ the monoclonal antibody according to claim 10 ~~claim 11~~.

24. (CURRENTLY AMENDED) A ~~The~~ method according to claim 20 ~~any one of claims 20 to 23,~~ wherein the cancer is a gastro-intestinal cancer.

25. (CURRENTLY AMENDED) A vaccine comprising a nucleic acid molecule ~~having a~~ comprising the nucleic acid molecule according to claim 1 ~~sequence as defined in any of claims 1 to 4 or~~ a pharmaceutically effective fragment ~~thereof thereof,~~ and a pharmaceutically acceptable carrier.

26. (CURRENTLY AMENDED) A vaccine comprising a ~~polypeptide~~the protein according to claim 7 ~~any of claims 7 to 9~~ or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

27. (CURRENTLY AMENDED) ~~A~~The polypeptide according to claim 7 ~~claims 7 to 9~~ or a pharmaceutically effective fragment thereof, attached to a carrier ~~protein~~protein.

28. (NEW) A kit comprising the protein according to claim 7 for use with a method of detecting or monitoring cancer.

29. (NEW) A kit comprising the monoclonal antibody according to claim 10 for use with a method of detecting or monitoring cancer.

30. (NEW) An immunogenic composition comprising a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

31. (NEW) An immunogenic composition comprising the protein according to claim 7 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.